Loading clinical trials...

Effect of a Modified 5:2 Intermittent Fasting Diet on Population With Overweight or Obesity in China | Clinical Trials | Clareo Health

COMPLETEDNA

Effect of a Modified 5:2 Intermittent Fasting Diet on Population With Overweight or Obesity in China

Effect of a Modified 5:2 Intermittent Fasting Diet on Population With Overweight or Obesity in China: A Self-controlled Clinical Trial

NCT06552403•Zhejiang Provincial Tongde Hospital

View on ClinicalTrials.gov

Summary

This study aimed to investigate the effects of the modified 5:2 IF dietary intervention on the Chinese population with overweight or obesity based on a self-controlled clinical trial.

Detailed Description

There are fewer studies on the influence of dietary interventions on the Chinese populations with obesity, and the degree of obesity, body fat distribution, dietary pattern and structure, and metabolic status of populations with obesity are different between the Chinese and European populations. The effects of a 5:2 IF dietary intervention on the Chinese population with overweight or obesity are unclear. Therefore, this study aimed to investigate the effects of the modified 5:2 IF dietary intervention on the Chinese population with overweight or obesity based on a self-controlled clinical trial.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. participants aged 18 to 60 years
•2. participants with a body mass index (BMI) ≥ 24 kg/m2
•3. participants engaged in light physical labor and their weight was relatively stable.

Exclusion Criteria

•1. participants taking any medication with an effect on body weight in the three months prior to enrollment;
•2. participants with liver or kidney dysfunction (liver enzymes ≥ 2 times normal; blood creatinine \> the upper limit of normal);
•3. participants with a history of cardiovascular disease (e.g., coronary heart disease, stroke);
•4. participants with malignant tumors;
•5. women during pregnancy or breastfeeding;
•6. participants deemed unsuitable by the investigator to participate in this trial.

Locations (1)

Xiaoli Wang

Hangzhou, China

Key Dates

Start Date

January 1, 2022

Primary Completion Date

December 31, 2023

Completion Date

December 31, 2023

Last Updated

August 14, 2024

Enrollment

ACTUAL participants

Conditions

Overweight or Obesity

Interventions

A modified 5:2 intermittent fasting diet

DIETARY_SUPPLEMENT

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

NCT07160400

Part A: Healthy Part B: Overweight or Obesity

View study

RECRUITINGPHASE1

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

NCT07150962

Overweight or Obesity

View study

RECRUITINGPHASE3

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 14, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of a Modified 5:2 Intermittent Fasting Diet on Population With Overweight or Obesity in China

Inclusion Criteria

Exclusion Criteria

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Weight Reduction in CLBP

A Study of BGM0504 Injection in Participants with Obesity or Overweight

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss